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Abstract
Background: Resting heart rate (HR) has been proven to influence long-term prognosis in 
patients with chronic heart failure (HF). The aim of this study was to assess the relationship 
between resting HR at hospital admission and hospital outcome in patients with HF.
Methods: The study included Polish patients admitted to hospital due to HF who agreed to 
participate in Heart Failure Pilot Survey of the European Society of Cardiology.
Results: The final analysis included 598 patients. Median HR at hospital admission was  
80 bpm. In univariate analyses, higher HR at admission was associated with more frequent use 
of inotropic support (p = 0.0462) and diuretics (p = 0.0426), worse clinical (New York Heart 
Association — NYHA) status at discharge (p = 0.0483), longer hospital stay (p = 0.0303) and 
higher in-hospital mortality (p = 0.003). Compared to patients who survived, patients who died 
during hospitalization (n = 21; 3.5%) were older, more often had a history of stroke or tran-
sient ischemic attack and were characterized by higher NYHA class, higher HR at admission, 
lower systolic and diastolic blood pressure at admission, lower ejection fraction, lower glomeru-
lar filtration rate, and lower natrium and hemoglobin concentrations at hospital admission. In 
multivariate analysis, higher HR at admission (OR 1.594 [per 10 bpm]; 95% CI 1.061–2.395; 
p = 0.0248) and lower natrium concentration at admission (OR 0.767 [per 1 mmol/L];  
95% CI 0.618–0.952; p = 0.0162) were the only independent predictors of in-hospital mortality.
Conclusions: In patients with HF, higher resting HR at hospital admission is associated with 
increased in-hospital mortality. (Cardiol J 2014; 21, 4: 425–433)
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Introduction
Over the last few decades, the incidence and 
prevalence of chronic heart failure (HF) have been 
constantly increasing. This is a result of growing 
life expectancy and aging of modern societies, as 
well as advances in the treatment of acute coronary 
syndromes which lead to an increased number of 
survivors with left ventricular dysfunction [1].
Randomized clinical trials and large-scale 
registries are both helpful research tools. How-
ever, contrary to clinical trials, the advantage 
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of registries is that they reflect real-life patient 
populations. The aim of the Heart Failure Pilot 
Survey of the European Society of Cardiology was 
to assess clinical profile, pharmacotherapy and 
clinical course in HF patients across Europe [2].
Despite recent progress in pharmaco- and 
electrotherapy, prognosis in HF remains poor. 
The Systolic Heart Failure Treatment with the If 
Inhibitor Ivabradine Trial (SHIFT) demonstrated 
that in patients with chronic systolic HF higher 
resting heart rate (RHR) was associated with worse 
long-term prognosis [3]. The aim of this study was 
to assess the impact of RHR at hospital admission 
on short-term outcome in a Polish population of 
patients hospitalized for HF, based on data from 
the Heart Failure Pilot Survey.
Methods
Study population
The Heart Failure Pilot Survey was conducted 
by the European Society of Cardiology within 
the scope of the EURObservational Research 
Programme. It was a prospective, multicenter, 
observational survey of HF patients in 12 European 
countries. The survey included adult (i.e. over 
18 years old) patients with HF — both, outpatients 
with HF seen in ambulatory care, as well as pa-
tients admitted to hospital for acute or chronic HF. 
There were no specific exclusion criteria. Patients 
were enrolled in the study if they presented to 
hospital or outpatient clinic on one particular day 
of the week (chosen by the participating center) 
from October 2009 to May 2010.
Data regarding demographics, HF etiology and 
severity, clinical presentation, concomitant diseas-
es, diagnostic tests’ results, previous and current 
treatment and — in case of inpatients — clinical 
course of index hospitalization were collected 
in 136 European cardiology centers, including 
29 centers from Poland, and entered anonymously 
to on-line electronic Case Report Forms.
The survey was approved by the local Ethical 
Review Board. All the patients included into the 
survey were provided with detailed information 
on the aim, scope and methodology of the study. 
Signed informed consent was obtained from each 
of them.
The current analysis included Polish popula-
tion of Heart Failure Pilot Survey and only inpa-
tients (i.e. patients who were admitted to hospital). 
In order to assess the prognostic significance of 
baseline RHR, patients presenting with bradyar-
rhythmia or ventricular tachyarrhythmia as a rea-
son for HF decompensation and index hospitaliza-
tion, were excluded from the analysis.
Study endpoints
The primary endpoint was death during index 
hospitalization. Secondary endpoints included 
duration of hospital stay, time in Intensive Cardiac-
-Care Unit (ICCU), need for inotropic support and 
diuretic treatment, and clinical status expressed 
as New York Heart Association (NYHA) class at 
hospital discharge.
Statistical analysis
Categorical data were presented as number of 
patients and percentages. For ordinal variables and 
non-normally distributed continuous variables, me-
dian value and interquartile range (IQR) were used. 
Type of distribution was calculated by Shapiro-Wilk 
test with an alpha level set at 0.05. Significance of 
differences between groups was determined by 
Fisher’s exact test for categorical variables and 
Mann-Whitney U test for ordinal or non-normally 
distributed continuous variables. To determine the 
risk factors of in-hospital mortality, univariate and 
multivariate logistic regressions were performed. 
In multivariate logistic regression model all factors 
with p values lower than 0.1 in univariate analyses 
were used. Statistical significance was considered 
for p values lower than 0.05. Statistical analyses 
were performed using SAS software, version 9.2.
Results
Study group selection
Out of 5,118 patients included in the Heart 
Failure Pilot Survey across Europe, 893 patients 
were enrolled in Polish centers. In the Polish popu-
lation of the registry, there were 650 inpatients. 
Thirty patients were admitted to hospital due to 
ventricular tachyarrhythmia and 21 patients due to 
bradyarrhythmia — those patients were excluded 
from the analysis. Data regarding RHR at hospital 
admission were missing for one of the remaining 
patients. Therefore, the final analysis included 
598 patients hospitalized due to HF.
The flow chart of patient enrollment in the 
study is shown in Figure 1.
Study group characteristics
Baseline characteristics of the study group are 
presented in Table 1. Median age in the analyzed 
group was 69 (IQR: 58–78) years, 386 (64.6%) 
patients were male. In 358 (59.9%) patients HF 
was assumed to have ischemic etiology and in 
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Figure 1. Flow chart of patient enrollment in the current 
analysis.
242 (40.5%) patients this had been previously 
confirmed by coronary angiography. Other causes 
of HF in the study group were: valvular heart 
disease (72 [12.0%] patients), hypertension (66 
[11.0%]), dilated cardiomyopathy (59 [9.9%]) and 
tachycardia-induced cardiomyopathy (9 [1.5%]). 
In 34 (5.7%) patients the etiology of HF was not 
defined by investigators.
The most common reason for HF decompensa-
tion leading to index hospitalization was acute coro-
nary syndrome (in 179 [30.0%] patients). Other 
triggering factors of HF decompensation leading to 
index hospitalization were: atrial fibrillation (AF) 
(103 [17.3%] patients), uncontrolled hyperten-
sion (91 [15.2%]), HF treatment non-compliance 
(89 [14.9%]), infection (51 [8.5%]), renal dysfunction 
(43 [7.2%]), anemia (29 [4.9%]), iatrogenic effect 
(7 [1.2%]) and “other” causes (240 [40.2%]) — with 
a possibility to name more than one reason of HF 
decompensation for each patient.
Median RHR at hospital admission was 
80 (IQR: 70–100) bpm. Electrocardiogram at hos-
pital admission was available for 576 patients, 
with sinus rhythm (SR) in 370 patients, AF (as the 
leading rhythm) in 150 patients, paced rhythm in 
54 patients and “other” rhythm in 2 patients. Four 
hundred and two patients received beta-blockers 
before index hospitalization, including: carvedilol 
(188 patients), bisoprolol (93), metoprolol (91), 
sotalol (13), nebivolol (7), propranolol (5), atenolol 
(3) and betaxolol (2 patients). There was no distinc-
tion between metoprolol succinate and metoprolol 
tartrate in the Heart Failure Pilot Survey Case 
Report Forms. Only 39 patients (9.7% out of 402 
patients) received target doses of beta-blockers 
recommended by the current guidelines (i.e. 
bisoprolol 10 mg daily, carvedilol 50 mg daily, me-
toprolol 200 mg daily and nebivolol 10 mg daily) [4].
Median NYHA class at admission was III (IQR: 
II–IV). Median left ventricular ejection fraction 
(LVEF) in the study group was 37% (IQR: 27–49%).
Primary endpoint
Twenty-one patients (3.5% of the study group) 
died during index hospitalization. Compared to 
patients who survived, patients who died were 
older, more often had a history of stroke or tran-
sient ischemic attack (TIA). These patients were 
characterized by several characteristics at admis-
sion: worse clinical presentation (higher NYHA 
class), higher HR, lower systolic and diastolic blood 
pressure, lower LVEF, lower glomerular filtration 
rate (GFR) and lower natrium and hemoglobin 
concentrations, as shown in Table 1.
In univariate analyses, factors that predicted 
death during index hospitalization were: higher 
age, a history of a previous stroke or TIA, higher 
NYHA class at admission, higher HR at admission, 
lower systolic and diastolic blood pressure at ad-
mission, lower LVEF, lower GFR and lower hemo-
globin and natrium concentrations at admission. 
A trend was observed for previous statin treatment 
and acute coronary syndrome as a reason for index 
hospitalization. Univariate analyses are shown in 
Table 2.
In multivariate analysis, higher HR at admis-
sion (OR 1.594 [per 10 bpm]; 95% CI 1.061–2.395; 
p = 0.0248) and lower natrium concentration at 
admission (OR 0.767 [per 1 mmol/L]; 95% CI 
0.618–0.952; p = 0.0162) were the only independ-
ent predictors of in-hospital mortality (Table 3). 
A trend was observed for lower LVEF (p = 0.0591) 
and lower hemoglobin concentrations (p = 0.0709). 
Due to lack of complete data for some of the pa-
tients in the registry, the multivariate analysis 
included only those patients (425 out of 598) for 
whom all required parameters were available.
We also performed additional analyses, sepa-
rately for 370 patients with SR and for 150 patients 
with AF at hospital admission, to evaluate the 
impact of resting HR at admission on in-hospital 
mortality in those two subgroups of patients. In 
univariate analyses we observed a significant as-
sociation between higher HR and primary endpoint 
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in patients with AF (OR 1.37 [per 10 bpm]; 95% 
CI 1.00–1.87; p = 0.0495) and a borderline asso-
ciation in patients with SR (OR 1.26 [per 10 bpm]; 
95% CI 0.99–1.61; p = 0.058). However, none of 
the predictive factors from the univariate analy-
ses was found to be an independent risk factor 
in multivariate analyses. That was most probably 
a result of insufficient statistical power due to 
a very small number of events in both subgroups 
(4 deaths in 132 patients with complete data availa-
ble for multivariate analysis in the subgroup with AF 
and 5 deaths in 274 patients with complete data 
available for multivariate analysis in the subgroup 
with SR).
Table 1. Baseline characteristics of patients who survived and patients who died during hospitalization. 
In each bar, a total number (n) of patients for whom the given variable was available in the registry is 
shown. Continuous and ordinal variables are shown as a median value and interquartile range (IQR).
Alive (n = 577) Dead (n = 21) P
Demographics
Age [years] 69 (58–77); n = 577 80 (67–84); n = 21 0.0036
Male 64.8% (374/577) 57.1% (12/21) 0.49
Body mass index [kg/m2] 27.7 (24.4–31.3), n = 514 26.2 (24.8–31.6), n = 14 0.85
Heart failure (HF)
Ischemic etiology of HF 59.8% (345/577) 61.9% (13/21) 1.0
LVEF [%] 37 (27–50), n = 510 27 (20–36), n = 15 0.0092
Medical history
Current smoking 55.5% (320/577) 57.1% (12/21) 1.0
Coronary artery disease 58.5% (337/576) 71.4% (15/21) 0.27
Previous stroke or TIA 9.4% (54/575) 23.8% (5/21) 0.046
Diabetes mellitus 35.0% (202/577) 47.6% (10/21) 0.25
Hypertension 66.7% (385/577) 76.2% (16/21) 0.47
COPD 12.9% (74/575) 14.3% (3/21) 0.74
Chronic renal disease 22.4% (129/576) 38.1% (8/21) 0.11
Previous pharmacotherapy
Previous treatment with ACEI 61.6% (333/541) 63.2% (12/19) 1.0
Previous treatment with ARB 6.9% (37/539) 5.3% (1/19) 1.0
Previous treatment with ACEI or ARB 1.5% (8/539) 0.0% (0/19) 1.0
Previous treatment with beta-blockers 72.3% (391/541) 57.9% (11/19) 0.19
Previous treatment with aldosterone antagonists 41.4% (224/541) 42.1% (8/19) 1.0
Previous treatment with statin 53.0% (287/541) 31.6% (6/19) 0.0997
Index hospitalization
ACS as a cause of HF decompensation 29.3% (169/576) 47.6% (10/21) 0.088
HR at admission [bpm] 80 (70–100), n = 577 100 (80–130), n = 21 0.019
AF at admission 34.1% (197/577) 42.8% (9/21) 0.48
SBP at admission [mm Hg] 130 (115–150), n = 576 110 (90–130), n = 21 0.001
DBP at admission [mm Hg] 80 (70–90), n = 576 70 (60–80), n = 21 0.0017
NYHA class at admission III (II–IV), n = 575 IV (IV–IV), n = 21 < 0.0001
NYHA class I 1.4% (8/575) 0.0% (0/21)
NYHA class II 24.7% (142/575) 0.0% (0/21)
NYHA class III 49.4% (284/575) 23.8% (5/21)
NYHA class IV 24.5% (141/575) 76.2% (16/21) 
Hemoglobin concentration at admission [g/dL] 13.3 (12.1–14.6), n = 564 12.1 (11.0–13.7), n = 21 0.014
GFR at admission [mL/min/1.73 m2] 65.9 (46.2–93.3), n = 509 42.9 (30.3–58.3), n = 13 0.0192
Natrium concentration at admission [mmol/L] 138.9 (136.0–141.0), n = 568 135.0 (132.9–138.8), n = 21 0.0052
HF — heart failure; LVEF — left ventricular ejection fraction; TIA — transient ischemic attack; COPD — chronic obstructive pulmonary disease; 
ACEI — angiotensin-converting-enzyme inhibitor; ARB — angiotensin receptor blocker; ACS — acute coronary syndrome; HR — heart rate; 
AF — atrial fibrillation; SBP — systolic blood pressure; DBP — diastolic blood pressure; NYHA — New York Heart Association; GFR — glo-
merular filtration rate
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Secondary endpoints
Median duration of hospital stay was 7 (IQR: 
4–11) days, and median time spent in ICCU was 
1 (IQR: 0–5) day. Sixty-two (10.4%) patients re-
quired inotropic support and 469 (78.4%) patients 
received diuretic treatment. Median NYHA class 
at discharge was II (IQR: II–III).
In univariate analyses, higher HR at hospital 
admission was associated with a more frequent 
use of inotropic support (p = 0.0462; OR [per 
10 bpm] 1.115; 95% CI 1.002–1.241) and diuret-
ics (p = 0.0426; OR [per 10 bpm] 1.104; 95% CI 
1.003–1.215), worse clinical status (higher NYHA 
class) at discharge (p = 0.0483; r = 0.0819), and 
longer hospital stay (p = 0.0303; r = 0.0894). 
There was no relation between HR and time in 
ICCU (p= 0.1644).
Discussion
In the Polish population of patients hospital-
ized for HF, RHR at admission was found to be 
a predictor of in-hospital mortality, independently 
of other markers of the severity of HF decompen-
sation, such as blood pressure and clinical status 
(NYHA class) at admission. An increase in HR of 
10 bpm was followed by an almost 60% increase 
Table 2. Univariate analyses of predictors of in-hospital mortality.
Odds ratio (95% CI) P
Demographics
Age [per 10 years] 1.79 (1.16–2.75) 0.008
Male 0.72 (0.30–1.73) 0.46
Body mass index [per 1 kg/m2] 1.00 (0.91–1.10) 0.99
Heart failure (HF)
Ischemic etiology of HF 1.09 (0.45–2.68) 0.84
Left ventricular ejection fraction [per 5%] 0.74 (0.59–0.93) 0.011
Medical history
Current smoking 1.06 (0.44–2.57) 0.89
Coronary artery disease 1.78 (0.68–4.64) 0.24
Previous stroke or TIA 3.03 (1.07–8.59) 0.037
Diabtes mellitus 1.70 (0.71–4.1) 0.24
Hypertension 1.61 (0.58–4.47) 0.36
Chronic obstructive pulmonary disease 1.133 (0.33–3.94) 0.84
Chronic renal disease 2.12 (0.86–5.23) 0.102
Previous pharmacotherapy
Previous treatment with ACEI 1.07 (0.62–2.77) 0.88
Previous treatment with ARB 0.76 (0.10–5.83) 0.79
Previous treatment with ACEI or ARB 1.0 (0–999) 0.99
Previous treatment with beta-blockers 0.53 (0.21–1.33) 0.17
Previous treatment with aldosterone antagonists 1.03 (0.41–2.60) 0.95
Previous treatment with statin 0.41 (0.15–1.08) 0.072
Index hospitalization
ACS as a cause of HF decompensation 2.20 (0.92–5.23) 0.078
Heart rate at admission [per 10 bpm] 1.27 (1.08–1.49) 0.003
Atrial fibrillation at admission 1.46 (0.60–3.51) 0.40
Systolic BP at admission [per 10 mm Hg] 0.72 (0.59–0.88) 0.0015
Diastolic BP at admission [per 10 mm Hg] 0.57 (0.42–0.79) 0.0007
NYHA class at admission 7.52 (2.9–19.4) < 0.0001
Hemoglobin concentration at admission [per 1 g/dL] 0.75 (0.62–0.93) 0.007
GFR at admission [per 10 mL/min/1.73 m2] 0.80 (0.65–0.99) 0.043
Natrium concentration at admission [per 1 mmol/L] 0.87 (0.79–0.94) 0.001
CI — confidence interval; HF — heart failure; TIA — transient ischemic attack; ACEI — angiotensin-converting-enzyme inhibitor; ARB — angio-
tensin receptor blocker; ACS — acute coronary syndrome; BP — blood pressure; NYHA — New York Heart Association; GFR — glomerular 
filtration rate 
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in the risk of death during hospitalization. The 
analysis included patients with SR, as well as pa-
tients with AF (as the leading rhythm) and patients 
with paced rhythm at hospital admission. Separate 
analyses of subgroups with SR and AF at hospital 
admission yielded equivocal results due to insuf-
ficient statistical power.
RHR at admission was also associated with 
worse clinical course during index hospitalization, 
with a more frequent need for inotropic support and 
diuretic treatment, worse clinical status at hospital 
discharge and longer hospital stay in univariate 
analyses. However, these associations were weak, 
as Spearman’s rank correlation coefficient (r) for 
relationship of HR with NYHA class and hospital 
stay were below 0.1.
Raised RHR is a known risk factor for unfa-
vorable outcome in HF. This was most evidently 
demonstrated in the SHIFT trial, which rand-
omized 6,558 patients with chronic, symptomatic 
HF, stable on current medication, with LVEF of 
35% or lower, SR and resting HR over 70 bpm to 
ivabradine or placebo. After a median follow-up for 
almost 2 years, an 18% risk reduction in primary 
endpoint (cardiovascular death or hospital admis-
sion for worsening HF) was observed for patients 
allocated to ivabradine group [5]. A post-hoc analy-
sis demonstrated that this effect was completely 
attributable to HR reduction on ivabradine therapy, 
as treatment results were neutralized after ad-
justment for change of HR at 28 days. In patients 
receiving placebo, baseline RHR over 87 bpm was 
associated with more than 2-fold higher risk for 
primary endpoint than baseline HR below 72 bpm 
[3]. Unlike the SHIFT trial, our study included 
patients with decompensated HF rather than stable 
chronic HF, irrespective of LVEF, with both, SR and 
AF, and focused on short-term prognosis.
A recent post-hoc analysis of another large, 
randomized clinical trial — Candesartan in Heart 
Failure: Assessment of Reduction in Mortality and 
Morbidity (CHARM) delivered results similar to 
conclusions from the SHIFT trial [6]. In a cohort 
of 7,599 patients with chronic, symptomatic HF, 
baseline HR in the highest tertile (with median 
HR of 85 bpm) was associated with a significantly 
higher risk of cardiovascular death and HF hos-
pitalization after 38 months compared with the 
lowest HR tertile (with median HR of 60 bpm). 
The relationship between HR and outcomes was 
similar in patients with LVEF below and over 40%. 
However, baseline HR had no predictive value in 
patients with AF [6].
A few other small, prospective, observational 
studies confirmed significance of RHR for prog-
nosis in chronic HF [7, 8]. Interestingly, higher 
HR correlated with increased risk of arrhythmic 
events in patients with dilated cardiomyopathy 
and an implantable cardioverter-defibrillator [9].
Baseline HR at hospital admission was also 
found to influence outcome in patients with acute, 
decompensated HF. Recently, three independ-
ent risk scores assessing short-term prognosis 
in patients with acute HF have been developed 
[10–12]. All these three predictive models were 
derived from data from large cohorts of patients 
admitted for acute HF (including 7,433; 2,015 and 
5,306 patients) and stratified the risk of death at 7 
Table 3. Multivariate analysis of predictors of in-hospital mortality (n = 425).
Odds ratio (95% CI) P
Age [per 10 years] 1.678 (0.578–4.868) 0.3408
Left ventricular ejection fraction [per 5%] 0.639 (0.401–1.017) 0.0591
Previous stroke or TIA 0.975 (0.061–15.677) 0.9860
Previous treatment with statin 0.518 (0.054–4.943) 0.5674
ACS as a cause of HF decompensation 0.689 (0.042–11.344) 0.7942
HR at admission [per 10 bpm.] 1.594 (1.061–2.395) 0.0248
Systolic BP at admission [per 10 mm Hg] 0.534 (0.196–1.453) 0.2195
Diastolic BP at admission [per 10 mm Hg] 1.997 (0.555–7.183) 0.2897
NYHA class at admission 3.354 (0.554–20.319) 0.1880
Hemoglobin concentration at admission [per 1 g/dL] 0.576 (0.316–1.048) 0.0709
GFR at admission [per 10 mL/min/1.73 m2] 0.883 (0.559–1.395) 0.5938
Natrium concentration at admission [per 1 mmol/L] 0.767 (0.618–0.952) 0.0162
CI — confidence interval; TIA — transient ischemic attack; ACS — acute coronary syndrome; HF — heart failure; HR — heart rate; BP — blood 
pressure; NYHA — New York Heart Association; GFR — glomerular filtration rate
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days, death or HF worsening at 7 days, and death at 
30 days, respectively. In all these studies, baseline HR 
turned out to be an independent prognostic factor 
and was incorporated in risk stratification models, 
together with other predictive factors, including 
age, comorbid conditions, baseline laboratory find-
ings and other presenting clinical features, such as 
systolic blood pressure. However, contrary to our 
study, none of these three studies included LVEF 
in the multivariate analysis [10–12].
The association between HR and prognosis in 
HF might partially explain the beneficial effect of 
beta-blockers in HF patients. Guidelines recom-
mend that patients with HF receive beta-blockers 
in doses used in the trials that have proven their 
efficacy [4]. However, a meta-analysis of 23 pro-
spective, randomized, placebo-controlled trials 
with beta-blockers, including over 19,000 patients 
with HF, revealed significant impact of achieved HR 
reduction on all-cause mortality, with no relation-
ship between mortality and beta-blockers dosing. 
Every HR reduction of 5 bpm with beta-blocker 
treatment was followed by an 18% reduction in the 
risk of death [13]. Another study, including 421 ho-
spitalized HF patients, demonstrated that not the 
discharge HR itself, but the extent of HR reduc-
tion achieved during treatment with beta-blockers 
determines the risk of future cardiac events [14].
The second independent predictor of in-hos-
pital mortality in our analysis was lower natrium 
concentrations. Hyponatremia is frequently ob-
served in patients with severe HF. Data from 
registries and randomized controlled trials indicate 
that 12–27% of patients admitted to hospital for HF 
are hyponatremic [15–19]. In HF, hyponateremia is 
believed to result from increased concentrations of 
antidiuretic hormone (ADH, vasopressin), the se-
cretion of which is stimulated by reduced systemic 
arterial blood pressure due to a low cardiac output, 
even in patients with volume overload and fluid 
retention. Long-term therapy with loop diuretics 
may aggravate hyponatremia [20].
Hyponatremia had previously been associated 
with unfavorable prognosis in HF. In observa-
tional studies, registries and post-hoc analyses of 
randomized clinical trials, it was reported to cor-
relate with all-cause and cardiac mortality (both 
in-hospital and long-term) as well as with the risk 
of re-hospitalization for HF [12, 15–19, 21–23].
So far, it is not clear whether hyponatremia it-
self deteriorates clinical outcome in HF or whether 
it is merely a marker of severity of HF or other 
comorbid conditions [20]. Interestingly, despite 
a proven relationship between hyponatremia and 
prognosis in HF, treatment with ADH receptor an-
tagonists, such as tolvaptan, had no impact on mor-
tality in HF [24]. Observational studies evaluating 
changes in plasma natrium in patients hospitalized 
for HF have brought conflicting results, with some 
evidence that correction of hyponatremia might 
lead to improvement in outcome [15, 18, 25–27].
In our study, in the multivariate analysis of 
independent predictors of in-hospital mortality we 
also observed a trend for lower LVEF and lower 
hemoglobin concentrations at admission. Both of 
these variables are known prognostic factors in HF 
patients [12, 21–23, 28–30]. It seems possible that 
due to a relatively small number of events these 
factors did not reach statistical significance in our 
analysis. In a cohort of 48,612 patients hospitalized 
for HF and enrolled in the Organized Program to 
Initiate Lifesaving Treatment in Hospitalized Pa-
tients with Heart Failure (OPTIMIZE-HF) registry 
independent predictors of in-hospital mortality 
included i.a. resting HR, natrium concentrations 
and presence of left ventricular systolic dysfunc-
tion [21].
Limitations of the study
The limitations of our study result from the 
type of data we analyzed. The advantage of regis-
tries is that they include a broad, diverse, real-life 
spectrum of patients, rather than a narrow, care-
fully selected patient subgroup as in clinical trials. 
However, important drawbacks of registries are: 
their retrospective and observational character, 
simplifications necessary for data unification for 
analysis, limited number of data collected, as well 
as incompleteness of the data. In our study data of 
425 (71%) out of 598 patients were complete and 
available for multivariate analysis. Furthermore, 
some potentially important variables, such as con-
centrations of B-type natriuretic peptide, were not 
available for analysis.
Conclusions
In Polish patients hospitalized for HF, higher 
HR at hospital admission was associated with in-
creased in-hospital mortality.
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